Literature DB >> 10845234

Primary T-cell lymphoma of the brain in children: a case report and literature review.

H al-Ghamdi1, R Sabbah, J Martin, Z Patay.   

Abstract

Described here are the clinical features and results of treatment in a 10-year-old Saudi Arabian girl with primary T-cell lymphoma of the central nervous system. At presentation the patient had nystagmus and ataxia. The diagnosis was established by tissue biopsy obtained from the cerebellum. Therapy included cranio-spinal irradiation and combination chemotherapy of a systemic high dose of methotrexate, cytosine, arabinoside, and L-asparaginase. Remission was obtained easily but was interrupted by a local intracranial relapse 57 months after diagnosis (37 months after cessation of therapy; at present the patient is still alive and receiving palliative treatment). This report is warranted because of the rarity of this condition in children.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10845234     DOI: 10.1080/088800100276343

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  3 in total

Review 1.  Primary T cell central nervous system lymphoblastic lymphoma in a child: case report and literature review.

Authors:  Marcus D Mazur; Vijay M Ravindra; Mouied Alashari; Elizabeth Raetz; Matthew M Poppe; Robert J Bollo
Journal:  Childs Nerv Syst       Date:  2015-02-15       Impact factor: 1.475

2.  The selective cytotoxic anti-cancer properties and proteomic analysis of Trigonella Foenum-Graecum.

Authors:  Abdulaziz Alsemari; Fahad Alkhodairy; Ahmad Aldakan; Mai Al-Mohanna; Eman Bahoush; Zakia Shinwari; Ayodele Alaiya
Journal:  BMC Complement Altern Med       Date:  2014-03-29       Impact factor: 3.659

Review 3.  The Healing-Promoting Properties of Selected Cyclitols-A Review.

Authors:  Agnieszka Owczarczyk-Saczonek; Lesław Bernard Lahuta; Magdalena Ligor; Waldemar Placek; Ryszard Józef Górecki; Bogusław Buszewski
Journal:  Nutrients       Date:  2018-12-03       Impact factor: 5.717

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.